Abstract |
Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.
|
Authors | Patrick Harrington, Katie J Doores, Deepti Radia, Amy O'Reilly, Ho Pui Jeff Lam, Jeffrey Seow, Carl Graham, Thomas Lechmere, Donal McLornan, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O'Sullivan, Kavita Raj, Shahram Kordasti, Michael H Malim, Claire Harrison, Hugues de Lavallade |
Journal | British journal of haematology
(Br J Haematol)
Vol. 194
Issue 6
Pg. 999-1006
(09 2021)
ISSN: 1365-2141 [Electronic] England |
PMID | 34085278
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. |
Chemical References |
- Antibodies, Neutralizing
- Antibodies, Viral
- COVID-19 Vaccines
- Immunoglobulin G
- Protein Kinase Inhibitors
- Spike Glycoprotein, Coronavirus
- BNT162 Vaccine
|
Topics |
- Adult
- Aged
- Antibodies, Neutralizing
(immunology)
- Antibodies, Viral
(immunology)
- BNT162 Vaccine
- CD4-Positive T-Lymphocytes
(immunology)
- CD8-Positive T-Lymphocytes
(immunology)
- COVID-19
(immunology, prevention & control)
- COVID-19 Vaccines
(administration & dosage, immunology)
- Female
- Hematologic Neoplasms
(drug therapy, immunology)
- Humans
- Immunity, Cellular
(drug effects)
- Immunoglobulin G
(immunology)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, immunology)
- Male
- Middle Aged
- Protein Kinase Inhibitors
(administration & dosage)
- SARS-CoV-2
(immunology)
- Spike Glycoprotein, Coronavirus
(immunology)
|